TherapeuticsMD, Near Term Catalysts and Analysts Review

TherapeuticsMD, Inc. (NASDAQ: TXMD) is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA™ technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.

In October, 2017, TXMD switched from a NYSE listing to a listing on the NASDAQ exchange. The ticker symbol remains the same.

The company last released its quarterly earnings results on Thursday, August 3rd. The company reported ($0.10) EPS for the quarter, exceeding analysts’ consensus estimates of ($0.11) by $0.01. The analyst expects the company to report earnings of ($0.09) per share for the current fiscal quarter. The company is expected to release its Q3 earnings report on, or about, November 2, 2017.

Several equities research analysts recently issued favorable reports on TXMD shares. Cantor Fitzgerald restated an “overweight” rating and set a $33.00 price objective on shares of TXMD on, August 15th. Morgan Stanley initiated coverage on, September 8th. They set an “equal weight” rating and a $6.00 target price. Jefferies Group LLC reaffirmed a “buy” rating and set a $15.00 target price on, August 11th. Oppenheimer Holdings, Inc. set a $10.00 target price and gave a “buy” rating on, October 16th. The company currently has an average rating of “Buy” and an average price target of $15.

The company has developed an asset called TX-004HR, which is for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a common symptom of vulvar and vaginal atrophy (VVA) caused due to menopause. It submitted the data to the FDA as part of a New Drug Application (NDA). However, the agency responded with a Complete Response Letter (CRL) detailing the fact that it required some long-term safety data before approval could be granted.

Subsequently, TherapeuticsMD collected the data and had already resubmitted it. On November 3, TXMD will sit down with the FDA as part of a type A meeting and will understand whether the data it has collected would be enough for approval or whether TherapeuticsMD will have to carry out additional trials to collect the information it needs.

If the concerned authorities accept data as is, TherapeuticsMD is likely to surge in anticipation of a near-term approval. On the flip side, If the FDA requires further data, TherapeuticsMD is very likely to still pick up an approval, but it’s going to have to spend some money conducting trials before it does.

Furthermore, there’s abundant historical data already available that signals to the long-term safety and viability of this sort of asset and there doesn’t look to be any material reason why TherapeuticsMD won’t be able to get the asset approved eventually.

The company recently announced the closing of its previously announced underwritten public offering of 12.4 million shares of its common stock.

At closing, TherapeuticsMD received net proceeds from the offering of approximately $68.5 million. The company intends to use a majority of the net proceeds from the offering to fund pre-commercialization and commercialization activities for TX-004HR and TX-001HR. As a result of this dilution, there has been some loss of investor confidence, which potentially contributed to the recent price drop (The stock price has dropped since the secondary offering; >20%)

Notwithstanding this dilution, the analysts believe that the overall fundamental remains intact for the company.  It’s just that the stock price tends to fall when a capital raise is announced. Also, for an early stage biotech company like this, with high cash burn rate and limited financing options, a secondary offering is often inevitable.

Markets are now looking to the upcoming quarterly result and the potential upside catalyst for the company and, if this news hits press favorably, the stock of the company will be on a rapid growth trajectory. Even if it misses, the subsequent dip in share price will serve as an option to make a position for the eventual upside run.

About the company: TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA™ technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.


Product Pipeline:

The company’s late-stage clinical pipeline includes two phases 3 product candidates:

  • TX-001HR for treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause and;
  • TX-004HR for treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause.


The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD® and BocaGreenMD® brands.


Industry overview:

About Vulvar and Vaginal Atrophy (VVA): An estimated 32 million women in the United States are currently suffering from symptoms of VVA, and only 2.3 million (7 percent) are currently being treated with prescription therapy. VVA symptoms can range from mild to severe and include dyspareunia, vaginal dryness, urinary tract infections, and vaginal bleeding associated with sexual activity. Vaginal dryness and dyspareunia are considered the most bothersome symptoms of VVA. Because of the chronic nature of VVA due to menopause, its symptoms will not likely resolve without intervention.




  • Multi-Billion Dollar Total Substitutable Market Opportunity. If approved, TX-001HR can provide a single pill solution for women and physicians who:
  • Demand an FDA-approved bio-identical combination hormone product
  • Do not trust compounded hormones


2nd Quarter 2017 Financial Results:

Net revenue from the company’s prescription prenatal vitamin business was approximately $4.3 million for the second quarter of 2017 compared with net revenue of approximately $4.4 million for the prior year’s quarter. These changes were primarily due to a decrease in the number of units sold.

Cost of goods sold was approximately $0.7 million for the second quarter of 2017, compared with approximately $1.1 million for the prior year’s quarter.

Net loss for the second quarter of 2017 was approximately $19.7 million, or $0.10 per basic and diluted share, compared with approximately $21.1 million, or $0.11 per basic and diluted share, for the second quarter of 2016.

At June 30, 2017, cash on hand was approximately $96.5 million, compared with approximately $131.5 million at December 31, 2016.


Key risk factors and potential stock drivers:

The company is optimistic about the positive outcome of the November 3 meeting. This meeting will be a critical catalyst for the company going forward.

The outcome of the upcoming milestones/catalysts could be the near-term trigger for the company. Any non-favorable developments could impinge the business and financial risk profile of the company.

TXMD may not be able to successfully develop, launch and commercialize TX-004 or any other potential future development programs.

Debt financing terms will play a significant role in the likelihood of further dilution. If the terms of the loan are unfavorable, management might potentially resort to the equity markets once again as the source of financing.

The company may experience financial, regulatory, or operational difficulties, which may impair its ability to commercialize their drug products. In fact, in the past, markets sold off on TherapeuticsMD heavily when the FDA issued the CRL to the company.


Stock Chart:


On Wednesday, October 25th, 2017, in intra-day trading, TXMD was at $5.00 (-1.4%) on volume of 833K shares exchanging hands. Market capitalization is $1.08 billion. The current RSI is 42.08

In the past 52 weeks, shares of TXMD have traded as low as $3.50 and as high as 8.30

At $5.00, shares of TXMD are trading below its 50-day moving average (MA) at $5.69 and below its 200-day MA at $5.58 as well.

The present support and resistance levels for the stock are at $4.89 & $5.12 respectively.


Welcome to Traders News Source

Are you up over 400% this year? Our members are…

Traders News Source recent profiles and track record, 440% in verifiable potential gains for our members on 3 small cap alerts alone! These are just three examples from over a dozen winners this year.


June 7th, 2017- (NASDAQ: ARCI) alerted at .55/share hit $1.00/share the next day and $1.75/share within 3 months for gains of over 200%.


March 27th, 2017- (NYSE: XXII) opened at $1.09/share hit a high of $3.03/share so far our member potential gains 200%.


February 7th, 2017 (NASDAQ: OBCI) opening at $4.10/share. This coverage was due to the consistent exceptional quarterly growth coupled with a special divvy issued last year and as anticipated was announced again this year. So far OBCI has traded as high as $5.90/share for potential gains of 43% so far.


So, if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.

We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.

Big Opportunities Trading Small Cap Stocks

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP – SMS/text alert service for free, simply text the word “Traders” to the phone number “25827” from your cell phone***





Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.

Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.

This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.

We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.

When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.

17B Disclosure

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.

TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.

Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.